Pfizer Nabs Extended Indication for Prevnar 13

Pfizer has received the greenlight from the FDA to stretch the age indication for its pneumococcal 13-valent conjugate vaccine Prevnar 13, to include adults between the ages of 18 and 49.

The vaccine — which is designed to prevent pneumonia and invasive diseases caused by streptococcus pneumoniae — is now the only pneumococcal vaccine approved for patients aged 6 weeks and over, according to the company.